ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
ACELYRIN, INC. (Nasdaq: SLRN) has formed a scientific and patient advisory board comprising leading experts and advocates in thyroid eye disease (TED). This board will provide strategic input, clinical expertise, and patient perspectives as ACELYRIN prepares to advance lonigutamab, a subcutaneously delivered IgG1 monoclonal antibody targeting the anti-insulin-like growth factor 1 (IGF-1) receptor, into Phase 3 clinical development for TED in the first quarter of 2025.
The advisory board includes renowned scientific advisors and a patient advocate, each bringing distinct expertise in TED. ACELYRIN aims to leverage their collective insights to execute its goal of delivering a potentially best-in-class subcutaneous anti-IGF-1R treatment for TED patients.
ACELYRIN, INC. (Nasdaq: SLRN) ha formato un comitato consultivo scientifico e per i pazienti composto da esperti e sostenitori di spicco nel campo della malattia oculare tiroidea (TED). Questo comitato fornirà input strategici, expertise cliniche e prospettive dei pazienti mentre ACELYRIN si prepara a sviluppare lonigutamab, un anticorpo monoclonale IgG1 somministrato per via sottocutanea che mira al recettore dell'insulina-like growth factor 1 (IGF-1), portandolo in sviluppo clinico di Fase 3 per TED nel primo trimestre del 2025.
Il comitato consultivo include rinomati consulenti scientifici e un sostenitore dei pazienti, ognuno con una competenza distinta nel campo della TED. ACELYRIN punta a sfruttare le loro intuizioni collettive per realizzare il suo obiettivo di offrire un trattamento sottocutaneo potenzialmente leader nella categoria per i pazienti con TED.
ACELYRIN, INC. (Nasdaq: SLRN) ha formado un consejo asesor científico y de pacientes que incluye a destacados expertos y defensores en la enfermedad ocular tiroidea (TED). Este consejo proporcionará aportes estratégicos, experiencia clínica y perspectivas de los pacientes mientras ACELYRIN se prepara para avanzar con lonigutamab, un anticuerpo monoclonal IgG1 administrado por vía subcutánea que se dirige al receptor del factor de crecimiento similar a la insulina 1 (IGF-1), hacia el desarrollo clínico de Fase 3 para TED en el primer trimestre de 2025.
El consejo asesor incluye reconocidos asesores científicos y un defensor de los pacientes, cada uno aportando una experiencia distinta en TED. ACELYRIN busca aprovechar sus insights colectivos para llevar a cabo su objetivo de ofrecer un tratamiento subcutáneo potencialmente líder en su clase para los pacientes con TED.
ACELYRIN, INC. (Nasdaq: SLRN)은 갑상선 안구 질환 (TED)의 주요 전문가 및 옹호자로 구성된 과학 및 환자 자문위원회를 구성했습니다. 이 위원회는 ACELYRIN이 2025년 1분기에 TED에 대한 lonigutamab, 즉 항 인슐린 유사 성장 인자 1 (IGF-1) 수용체를 겨냥한 피하 투여 IgG1 단클론 항체의 3상 임상 개발을 진행하기 위해 전략적 의견, 임상 전문 지식 및 환자 관점을 제공할 것입니다.
자문위원회에는 TED 분야에서 각기 다른 전문 지식을 지닌 저명한 과학 고문과 환자 옹호자가 포함되어 있습니다. ACELYRIN은 이들의 집단적인 통찰력을 활용하여 TED 환자에게 잠재적으로 최고의 피하 항 IGF-1R 치료제를 제공하는 목표를 실행할 계획입니다.
ACELYRIN, INC. (Nasdaq: SLRN) a formé un conseil consultatif scientifique et de patients composé d'experts et de défenseurs de premier plan dans le domaine de la maladie oculaire thyroïdienne (TED). Ce conseil fournira des contributions stratégiques, une expertise clinique et des perspectives de patients alors qu'ACELYRIN se prépare à faire avancer lonigutamab, un anticorps monoclonal IgG1 administré par voie sous-cutanée ciblant le récepteur du facteur de croissance semblable à l'insuline 1 (IGF-1), vers le développement clinique de Phase 3 pour TED au premier trimestre de 2025.
Le conseil consultatif comprend des conseillers scientifiques renommés et un défenseur des patients, chacun apportant une expertise distincte dans le domaine de la TED. ACELYRIN vise à tirer parti de leurs idées collectives pour réaliser son objectif de fournir un traitement anti-IGF-1R subcutané potentiellement de classe mondiale pour les patients TED.
ACELYRIN, INC. (Nasdaq: SLRN) hat ein wissenschaftliches und Patientenberatungsboard gebildet, das führende Experten und Anwälte für thyroid eye disease (TED) umfasst. Dieses Board wird strategische Beiträge, klinische Expertise und Patientenperspektiven liefern, während ACELYRIN sich darauf vorbereitet, lonigutamab, einen subkutan verabreichten IgG1-Monoklonalen Antikörper, der auf den Rezeptor für den insulinähnlichen Wachstumsfaktor 1 (IGF-1) abzielt, in die klinische Entwicklung der Phase 3 für TED im ersten Quartal 2025 voranzubringen.
Das Beratungsboard umfasst renommierte wissenschaftliche Berater und einen Patientenanwalt, die jeweils unterschiedliche Fachkenntnisse in TED mitbringen. ACELYRIN beabsichtigt, ihre kollektiven Erkenntnisse zu nutzen, um sein Ziel zu erreichen, eine potenziell führende subkutane Anti-IGF-1R-Therapie für TED-Patienten anzubieten.
- Formation of a scientific and patient advisory board with leading experts in thyroid eye disease
- Preparation for Phase 3 clinical development of lonigutamab in Q1 2025
- Potential to deliver a best-in-class subcutaneous anti-IGF-1R treatment for TED patients
- None.
Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first quarter of 2025
LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED). This group of advisors will provide important strategic input, clinical expertise and patient perspectives as ACELYRIN prepares to advance lonigutamab, a subcutaneously delivered IgG1 monoclonal antibody targeting the anti-insulin-like growth factor 1 (IGF-1) receptor, into Phase 3 clinical development for TED in the first quarter of 2025.
“Convening this esteemed group of clinical thought leaders and patient advocates is an important step forward for us as we prepare to advance lonigutamab into the pivotal Phase 3 program for TED,” said Shephard (Shep) Mpofu, M.D., Chief Medical Officer of ACELYRIN. “Each member brings distinct expertise spanning multiple facets of TED including disease pathology, clinical trial leadership and patient experience. We believe their collective insights will position us extremely well to execute on our goal of delivering the potentially best-in-class subcutaneous anti-IGF-1R treatment for TED patients.”
Inaugural members of the ACELYRIN scientific and patient advisory board are listed below; full bios are available on the ACELYRIN website.
Scientific Advisors
- George J. Kahaly, MD, PhD, Professor of Medicine and Endocrinology Metabolism and Chief Physician of the Endocrine Outpatient Clinic at the Johannes Gutenberg University Medical Center, Mainz, Germany;
- Andrea Lora Kossler, MD, FACS, Associate Professor of Ophthalmology at Stanford University School of Medicine and Director of the Oculofacial Plastic, Reconstructive Surgery and Orbital Oncology Service at the Byers Eye Institute at Stanford;
- Prem Subramanian, MD, PhD, Professor of Ophthalmology, Neurology, and Neurosurgery, University of Colorado School of Medicine; and
- Shoaib Ugradar, MD, Department of Orbital and Oculoplastic Surgery, private practice, Beverly Hills, California.
Patient Advisor
- Christine Gustafson, Executive Director and CEO of the TED Community Organization, the only global 501c3 nonprofit dedicated to Thyroid Eye Disease.
About Thyroid Eye Disease
Thyroid Eye Disease (TED) is a vision-threatening autoimmune disease in which there is both inflammation and expansion of the tissues behind the eye, resulting in eye bulging, known as proptosis, and the subsequent inability to close the eyelids. Double vision, or diplopia, can occur, as well as the potential for compression of the optic nerve, which can lead to blindness. Thus, TED is a progressive, chronic inflammatory disease. More than 100,000 people in the United States are estimated to suffer from TED.
About Lonigutamab
Lonigutamab is a humanized IgG1 monoclonal antibody targeting the anti-insulin-like growth factor 1 (IGF-1) receptor and is delivered subcutaneously. Relative to standard of care, lonigutamab binds to a distinct epitope, which results in internalization of the receptor within minutes, and in preclinical binding and functional laboratory assays, it has been shown to be 75-fold more potent. The characteristics of lonigutamab that enable subcutaneous delivery also enable the potential for longer-term, convenient dosing, which can potentially improve depth and durability of clinical response.
About ACELYRIN
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.
For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding ACELYRIN’s ability to address unmet needs of patients, business plans and potential future benefits of our pipeline. These forward-looking statements are based on ACELYRIN’s current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN’s actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN’s product candidates, the risk that future results could differ materially and adversely from early clinical data, and other risks and uncertainties affecting ACELYRIN including those described from time to time under the caption “Risk Factors” and elsewhere in ACELYRIN’s current and future reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.
FAQ
What is the purpose of ACELYRIN's new scientific and patient advisory board for thyroid eye disease?
When does ACELYRIN (SLRN) plan to initiate Phase 3 trials for lonigutamab in thyroid eye disease?
What is lonigutamab and how is it administered for thyroid eye disease treatment?
Who are the members of ACELYRIN's new scientific and patient advisory board for TED?
